Breaking the GLP-1 Cost Cycle: Transforming Access, Cutting Costs, and Shaping the Future of Obesity Care

As obesity rates rise, GLP-1 medications are gaining popularity. Yet, the multifactorial obesity epidemic presents challenges for your clients as more of their employees demand GLP-1’s. This white paper explores strategies to help clients cut costs, improve employee health outcomes, and achieve a measurable ROI.

Your clients are at a pivotal moment in managing employee health outcomes and healthcare costs as GLP-1 medications reshape the landscape. As a benefits advisor and partner, you’re uniquely positioned to guide them through the challenges posed by obesity-related expenses and the growing demand for GLP-1 medications.

This white paper offers actionable strategies you can bring to clients to tackle the challenges of obesity care. Inside, you’ll find insights on how to:

• Minimize GLP-1 medication costs without sacrificing care quality.
• Combine behavioral and medical interventions for improved outcomes.
• Increase medication adherence to enhance long-term success.
• Deliver measurable ROI with tailored, cost-effective strategies.
• Offer scalable solutions that address diverse workforce needs.